Petros Pharmaceuticals, Inc.
PTPI Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, revenue grew 1,070.6%, EPS grew 76.7% and free cash flow grew 71.3%, each against the same quarter a year earlier.
Follow PTPI
Petros Pharmaceuticals, Inc. (PTPI) EV/Sales
As of 16 October 2026, Petros Pharmaceuticals, Inc. (PTPI) trades at a EV/Sales of 0.4×. Over the past ten years it has ranged from −1.3× (March 2022) to 4.2× (March 2022); the current reading is higher than 70% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 1.0× | — |
| FY2023 | −0.3× | — |
| FY2022 | 1.2× | (34.89%) |
| FY2021 | 1.9× | 26.65% |
| FY2020 | 1.5× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 1.0× | (34.46%) |
| Sep 2024 | 1.6× | 102.42% |
| Jun 2024 | 0.8× | (4.00%) |
| Mar 2024 | 0.8× | — |
| 18 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SXTC China SXT Pharmaceuticals, Inc. compare | −5.9× |
| SBFM Sunshine Biopharma, Inc. compare | −0.3× |
| LSDIF Lucy Scientific Discovery Inc. compare | n/m |
| AKAN Akanda Corp. compare | n/m |
| PRFX PainReform Ltd. compare | n/m |
| IMCC IM Cannabis Corp. compare | 0.0× |
| PTPI Petros Pharmaceuticals, Inc. | 0.4× |
| NEPTF Neptune Wellness Solutions Inc. compare | 1.1× |
| BTAIQ BioXcel Therapeutics, Inc. compare | 228× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)